Drugs / ATP128
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04046445 | Jul 2019 → May 2025 overdue | metastasis from malignant tumor of colon, rectal cancer | Amal Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATP128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04046445 ↗ |
| Modality | Vaccine | “ATP128 is a self-adjuvanted chimeric recombinant protein vaccine” NCT04046445 ↗ |
| Route | Subcutaneous | “5-6 SC injections” NCT04046445 ↗ |